Physician profile
Charles C Johnson
NPI 1902906464
$240.79
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $121 · 2023: $84.75 · 2024: $35.54.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $120.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $120.50 | 2022 | |
| Glaxosmithkline, LLC. | $38.39 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $32.78 | 2023 | |
| Amgen INC. | $19.82 | 2024 | Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $15.72 | 2024 | |
| Novo Nordisk INC | $13.58 | 2023 | Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.